We are live on ! Find out more
AIM icon

AIM ImmunoTech
AIM

12 hedge funds and large institutions have $544K invested in AIM ImmunoTech in 2018 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

96% more capital inflows, than outflows

Capital inflows: $148K | Capital outflows: $75.8K

0.42% less ownership

Funds ownership: 3.95% → 3.53% (-0.42%)

25% less funds holding

Funds holding: 16 → 12 (-4)

50% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 4

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 4

Holders
12
Holders Change
-4
Holders Change %
-25%
% of All Funds
0.27%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
2
Reduced
4
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$75.2K
2
Citadel Advisors
Citadel Advisors
Florida
+$73.1K

Top Sellers

Rank Fund Capital Flow
1
Two Sigma Securities
Two Sigma Securities
New York
-$23K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$18K
3
Virtu Financial
Virtu Financial
New York
-$12.5K
4
Renaissance Technologies
Renaissance Technologies
New York
-$9K
5
Wells Fargo
Wells Fargo
California
-$7K

AIM Hedge Fund Activity: Q1 2018 in Review

12 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in AIM ImmunoTech (AIM) for Q1 2018, worth a combined $544K — up 25% from $434K a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of AIM and 0 opened new positions — a net loss of 4 holders — while 4 trimmed existing stakes and 2 added.

The largest buyer was Vanguard Group, adding an estimated $75.2K. The largest seller was Two Sigma Securities, cutting an estimated $23K.

  • 12 institutional investors held AIM ImmunoTech (AIM) as of Q1 2018, down from 16 in Q4 2017.
  • Funds reported $544K of AIM ImmunoTech stock for Q1 2018, up 25% quarter-over-quarter.
  • 0 funds opened new AIM ImmunoTech positions in Q1 2018 and 4 closed out, a net change of -4 holders.
  • The largest AIM ImmunoTech buyer in Q1 2018 was Vanguard Group, an estimated $75.2K added.
  • The largest AIM ImmunoTech seller in Q1 2018 was Two Sigma Securities, an estimated $23K sold.

Based on aggregated 13F filings for Q1 2018.